Exact Sciences
JP Morgan Healthcare Conference Day 3: Iovance, Elevation Oncology, Autolus, and More
Highlights of the third day included details on Iovance's regulatory progress on its TIL therapy, Elevation's seribantumab, and Precigen's UltraCAR-T therapies.
Exact Sciences Projects up to $475M in Q4 Revenues, Acquires Testing Lab, Inks Licensing Deal
The approximately 2 percent increase over Q4 2020 results beat analysts' expectations, and the acquisition news heralds market expansion into hereditary cancer testing.
RxPONDER Update Yields No Clear Guidance on Chemo Decisions for Younger Breast Cancer Patients
Premium
A large, randomized trial exploring the benefit of adding chemo to endocrine therapy for premenopausal women with Oncotype DX scores of 0 to 25 will likely be needed.
A multiomic study out of TGen and the Beat Childhood Cancer Research Consortium found potentially actionable tumor changes at the point of disease relapse.
Exact Sciences, NSABP Validating Ability of ctDNA Test to Detect MRD in Colorectal Cancer Patients
The study, called CORRECT-MRD II, is expected to enroll approximately 750 patients at 35 study sites in the US and Canada.